GovGazette
Menu

Historical award

Rigel Pharmaceuticals Inc

This record is historical buying context, not open work.

How current is this award history?

Fiscal year 2025: data through (12 days old).

Fiscal year 2026: data through (12 days old).

Official release availability details

Fiscal year 2025: This is the latest release listed by USAspending. A latest release can still omit recent activity.

Availability checked: .

Fiscal year 2026: This is the latest release listed by USAspending. A latest release can still omit recent activity.

Availability checked: .

Current award value
$749,999.00
Potential award value
$749,999.00
Total obligated to date
$749,999.00

Recorded work

RIGEL PHARMACEUTICALS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO EVALUATE THE IMPACT OF FOSTAMATINIB TREATMENT DURING HOSPITALIZATION RESULTING FROM ARDS ON LONG-TERM OUTCOMES INCLUDING CLINICAL, BIOMARKER, IMAGING, QOL, FUNCTIONAL AND LUNG FUNCTI

Award activity

Obligations in covered fiscal years
$0.00
Transactions in covered fiscal years
3

Award value and obligated funds describe different amounts. Review the official record for the full transaction history.

Record identifierCONT_AWD_75A50123C00012_7505_-NONE-_-NONE-